Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease.
about
Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patientsPerformance of a Predictive Model for Long-Term Hemoglobin Response to Darbepoetin and Iron Administration in a Large Cohort of Hemodialysis Patients.Dialysis and fatigue: implications for nurses--a case study analysisTreatment of erythropoietin deficiency in mice with systemically administered siRNA.Renal anemia: from incurable to curable.Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease.Pharmacokinetic and pharmacodynamic considerations on the erythropoietin effect and adverse events of darbepoetin.Erythropoietin in the critically ill: do we ask the right questions?Lack of hepcidin ameliorates anemia and improves growth in an adenine-induced mouse model of chronic kidney disease.Human pluripotent stem cell-derived erythropoietin-producing cells ameliorate renal anemia in mice.Haemolysis in haemodialysis.Haemoglobin levels and health-related quality of life in young and elderly patients on specialized predialysis care.Pathophysiological aspects of red blood cells in end-stage renal disease patients resistant to recombinant human erythropoietin therapy.A Woman with ESRD with Increasing Need for Erythropoietin to Maintain Hemoglobin.Epoetin beta pegol, but not recombinant erythropoietin, retains its hematopoietic effect in vivo in the presence of the sialic acid-metabolizing enzyme sialidase.The hypoxia inducible factor/erythropoietin (EPO)/EPO receptor pathway is disturbed in a rat model of chronic kidney disease related anemia.
P2860
Q35653263-443A4C0D-F05C-48DB-B249-9B15CD5C8CACQ35944877-522A579A-1DDE-44BD-8D98-F50E004CF4F6Q36149351-4DDE9641-DE68-4FE8-AC64-EC7D6D9C3E40Q36206440-3653B08D-83EC-4212-8545-FD2A927D68D4Q38123955-FCCBACEA-9EBD-4418-90CB-CE776451CCEAQ38134288-9F1B6FD8-597F-4C37-BF4F-C6856D5C9F33Q38281535-D27248BC-A439-42A2-9658-00FA988628C6Q42154729-3B07728B-83AD-424D-938F-B8018BBE6B24Q42784003-D4A34963-5821-45E1-AE7B-F22C13515BAFQ47734807-505DDC91-5981-4406-A4C0-9C294891A076Q47819838-A3289A10-FA7C-47E8-AEC0-E77B2620A0AAQ48086086-E5AC4245-B8F0-48F7-974C-C04739F2BF3FQ48124687-2E9C7361-6FE5-4B9F-A0C6-0115135A13F3Q53804522-47D97A0B-0043-47D1-9782-4388EFE25FFFQ54173895-35C88E71-0117-455D-A163-093614A7BB4BQ54454681-33F0E82D-B315-4DFB-95B8-25218ADD56B7
P2860
Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease.
@en
Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease.
@nl
type
label
Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease.
@en
Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease.
@nl
prefLabel
Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease.
@en
Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease.
@nl
P356
P1433
P1476
Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease.
@en
P2093
Oluwatoyin F Bamgbola
P2888
P304
P356
10.1038/KI.2011.179
P407
P577
2011-06-22T00:00:00Z